New York (March 26th, 2013) - Galena Biopharma, Inc. (NASDAQ: GALE) announced last week that it has entered into an agreement with Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, to acquire Abstral(R) (fentanyl) Sublingual Tablets for sale and distribution in the United States.
Abstral was approved by the U.S. Food and Drug Administration (FDA) in January 2011; and, it is the transmucosal immediate-release fentanyl (TIRF) market leader in Europe where it achieved sales of $54 million by ProStrakan/Kyowa Hakko Kirin in 2012. It is marketed in Canada by Paladin Labs, and has been filed for approval in Japan by Kyowa Hakko Kirin, Co. Ltd. In 2012, the U.S. market for TIRFs was $400 million.
Find out where GALE could be headed by getting the free and full trend analysis report here:
Array BioPharma, Inc. (NASDAQ: ARRY) was upgraded to Overweight from Neutral at Piper Jaffray. The firm also raised its price target on the stock to the $7.00 mark.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company’s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Get the latest trend analysis news on ARRY here:
MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed. Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.MonsterTradingAlerts.com
Disclosure: MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures. Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/
Alexander K. Neumann
Monster Trading Alerts